Technology

We have developed a modular platform with scalable equipment and cross-functional methods to support teams in achieving success. In the U.S., we focus on batch work from upstream to fill/finish, while our Munich operations emphasize upstream and quality process optimization, leveraging advanced bioreactors, robust analytics, and a secure supply chain.

Our Platform

We have built a modular platform from a developer’s perspective. Our scalable suite of equipment and cross-functional methods have been procured to help your team find success.

The key to the flexibility and functionality of our platform is:

Lab- to commercial-scale bioreactors that parallel process conditions across scales.
The right level of starting materials to ensure quality and productivity from the start.
Robust, fit-for-purpose analytics for in-depth product and process characterization.
Process enhancements like our proprietary EpyQ® AAV production system.
A secure supply chain, including fill/finish capabilities onsite.

Let’s solve your advanced therapy challenges together.

EpyQ® AAV Production System

In AAV production, traditional triple transfection (3 plasmids) is expensive and suffers from inherent limitations that can directly impact productivity and product quality. Our EpyQ® AAV production system is a two-plasmid transfection platform using one custom plasmid and one off the shelf plasmid to lower cost and complexity. In application, users can expect more rapid development of more robust AAV manufacturing processes with improved yields and reduced product-related impurities.

ELISA Kits

ABL has a strong core of expertise to help advance your candidate vaccines and therapeutics. Our p24 enzyme-linked immunosorbent assays (ELISA) kits are sold off the shelf to support your analytical biochemistry needs. Originally developed for HIV titer determination, the kits have evolved into a critical tool for the quantification of lentiviral vector (LVV) titers in cell and gene therapy applications.